The cyclooxygenase-2 inhibitor celecoxib effectively suppresses the development of non-melanoma skin cancers: results of a phase II/III clinical trial

被引：0
|
作者：
Elmets, C. A. [1 ]
Viner, J. L. [7 ]
Pentland, A. P. [9 ]
Cantrell, W. [1 ]
Bailey, H. [2 ]
Kang, S. [3 ]
Linden, K. G. [4 ]
Heffernan, M. [5 ]
Madeleine, D. [6 ]
Elewski, B. [1 ]
Umar, A. [7 ]
Lin, H. [1 ]
Bell, W. [1 ]
Gordon, G. [8 ]
机构：
[1] Univ Alabama, Birmingham, AL USA
[2] Univ Wisconsin, Madison, WI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Univ Calif Irvine, Irvine, CA USA
[5] Washington Univ, St Louis, MO USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] NCI, Bethesda, MD 20892 USA
[8] GD Searle Inc, Skokie, IL USA
[9] Univ Rochester, Rochester, NY USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2009年 / 129卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
325
引用
收藏
页码：S55 / S55
页数：1
相关论文
共 50 条
  • [31] Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)
    Edelman, Martin J.
    Wang, Xiaofei
    Hodgson, Lydia
    Cheney, Richard T.
    Baggstrom, Maria Q.
    Thomas, Sachdev P.
    Gajra, Ajeet
    Bertino, Erin
    Reckamp, Karen L.
    Molina, Julian
    Schiller, Joan H.
    Mitchell-Richards, Kisha
    Friedman, Paula N.
    Ritter, Jon
    Milne, Ginger
    Hahn, Olwen M.
    Stinchcombe, Thomas E.
    Vokes, Everett E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2184 - +
  • [32] Study protocol designed to investigate tumour response to calcium electroporation in cancers affecting the skin: a non-randomised phase II clinical trial
    Vissing, Mille
    Ploen, John
    Pervan, Mascha
    Vestergaard, Kitt
    Schnefeldt, Mazen
    Frandsen, Stine Krog
    Rafaelsen, Soren Rafael
    Lindhardt, Christina Louise
    Jensen, Lars Henrik
    Rody, Achim
    Gehl, Julie
    BMJ OPEN, 2021, 11 (06):
  • [33] PHASE-II TRIAL OF COMBINATION TREATMENT OF INTERFERON-ALFA, CIMETIDINE, CYCLOOXYGENASE-2 INHIBITOR AND RENIN-ANGIOTENSIN-SYSTEM INHIBITOR (I-CCA) FOR METASTATIC RENAL CELL CARCINOMA
    Tatokoro, M.
    Fujii, Y.
    Kawakami, S.
    Saito, K.
    Koga, F.
    Masuda, H.
    Kihara, K.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 230 - 230
  • [34] Phase-II trial of combination treatment of interferon-α, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma
    Tatokoro, Manabu
    Fujii, Yasuhisa
    Kawakami, Satoru
    Saito, Kazutaka
    Koga, Fumitaka
    Matsuoka, Yoh
    Iimura, Yasumasa
    Masuda, Hitoshi
    Kihara, Kazunori
    CANCER SCIENCE, 2011, 102 (01) : 137 - 143
  • [35] THE ROLE OF COX-2 INHIBITOR (CELECOXIB) IN COMBINATION WITH CHEMO-RADIOTHERAPY IN HEAD AND NECK CARCINOMA TO REDUCE ACUTE TOXICITIES, PHASE III, RANDOMIZED CLINICAL TRIAL
    Aghili, M.
    Mojahed, M.
    Kazemian, A.
    Izadi, S.
    Farhan, F.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S151 - S151
  • [36] A phase II study of carboplatin (C) and weekly paclitaxel (P) with a selective cyclooxygenase-2 (COX-2) inhibitor, meloxicam, in advanced non-small cell lung cancer (NSCLC)
    Suzuki, R.
    Yamamoto, M.
    Saka, H.
    Taniguchi, H.
    Shindo, J.
    Tanikawa, Y.
    Nomura, S.
    Oishi, T.
    Hasegawa, Y.
    Shimokata, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non-Small-Cell Lung Cancer: The NVALT-4 Study
    Groen, Harry J. M.
    Sietsma, Hannie
    Vincent, Andrew
    Hochstenbag, Monique M. H.
    van Putten, John W. G.
    van den Berg, Anke
    Dalesio, Otilia
    Biesma, Bonne
    Smit, Hans J. M.
    Termeer, Arien
    Hiltermann, T. Jeroen N.
    van den Borne, Ben E. E. M.
    Schramel, Franz M. N. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4320 - 4326
  • [38] 123I-BZA2 as a Melanin-Targeted Radiotracer for the Identification of Melanoma Metastases: Results and Perspectives of a Multicenter Phase III Clinical Trial
    Cachin, Florent
    Miot-Noirault, Elisabeth
    Gillet, Brigitte
    Isnardi, Vanina
    Labeille, Bruno
    Payoux, Pierre
    Meyer, Nicolas
    Cammilleri, Serge
    Gaudy, Caroline
    Razzouk-Cadet, Micheline
    Lacour, Jean Philippe
    Granel-Brocard, Florence
    Tychyj, Christelle
    Benbouzid, Fathalah
    Grange, Jean Daniel
    Baulieu, Franc Oise
    Kelly, Antony
    Merlin, Charles
    Mestas, Danielle
    Gachon, Francoise
    Chezal, Jean Michel
    Degoul, Francoise
    D'Incan, Michel
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01) : 15 - 22
  • [39] THE ROLE OF COX-2 INHIBITOR (CELECOXIB) IN COMBINATION WITH CHEMO-RADIOTHERAPY, IN IMPROVEMENT OF THE SURVIVAL AND RESPONSE RATE IN HEAD AND NECK CARCINOMA, PHASE III. RANDOMIZED CLINICAL TRIAL
    Aghili, M.
    Izadi, S.
    Mojahed, M.
    Kazemian, A.
    Farhan, F.
    Samiei, F.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S66 - S66
  • [40] Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants A Phase 2 Randomized Clinical Trial
    Bi, Nan
    Liang, Jun
    Zhou, Zongmei
    Chen, Dongfu
    Fu, Zhixue
    Yang, Xu
    Feng, QinFu
    Hui, Zhouguang
    Xiao, Zefen
    Lv, Jima
    Wang, Xiaozhen
    Zhang, Tao
    Wang, Xin
    Deng, Lei
    Wang, Wenqing
    Wang, Jingbo
    Liu, Lipin
    Hu, Chen
    Wang, Luhua
    JAMA NETWORK OPEN, 2019, 2 (12)
12345